How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/refractory-chronic-lymphocytic-leukemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Refractory chronic lymphocytic leukemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Refractory chronic lymphocytic leukemia (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Refractory chronic lymphocytic leukemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Campath	ALEMTUZUMAB	Sanofi	CD52-directed Cytolytic Antibody [EPC]	CAMPATH-1 antigen		2001-01-01
Campath	Campath	National Heart, Lung, and Blood Institute (NHLBI)		CAMPATH-1 antigen

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in Refractory chronic lymphocytic leukemia
Sanofi · 1 drug in Refractory chronic lymphocytic leukemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Refractory chronic lymphocytic leukemia:

Cite this brief

Drug Landscape (2026). Refractory chronic lymphocytic leukemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/refractory-chronic-lymphocytic-leukemia. Accessed 2026-06-10.

Refractory chronic lymphocytic leukemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing